UNSPSC 51181613: Calcitonin

This classification denotes a peptide hormone with the molecular formula C145H240N44O48S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DF35I47HCM, more generally known as calcitonin. European Medicines Agency schedules calcitonin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00948MIG. The term CALCITONIN is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 13 no. 1, 1999, list 41.

CALCITONIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule calcitonin under HS 29371900 and SITC 54154. As of Q4 2014, CALCITONIN remains the US FDA Preferred Term for this commodity. Calcitonin bears US NLM identifiers UMLS ID C0006668 and NCI Concept Code C2281.

UNSPSC 51181613 Calcitonin, a Commodity code, addresses pharmaceutical products that state and local government health systems and cooperative purchasing alliances procure through multi-source generic and branded pharmaceutical supply agreements. The work involves supplying FDA-compliant pharmaceutical products with certified manufacturing practices, negotiated pricing across flat-fee, net-price, and WAC-minus structures, and direct relationships with authorized pharmaceutical wholesalers to serve state and local health facilities, correctional systems, and other public-sector patient-care settings.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (RFP S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota, Oregon, and other MMCAP member states. Proposals were due March 26, 2026, with awarded vendors to be identified by May 15, 2026 and contract performance beginning July 1, 2026. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co., LLC), certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and carry commercial general liability insurance of $5 million per occurrence. The RFP weighted evaluation 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and 15 percent on combined administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. The contract term spans two years for new vendors with optional extensions, while incumbent vendors' amendments extend through June 30, 2028.